Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus).

Meloxicam is a nonsteroidal anti-inflammatory drug commonly used in avian species. In this study, the pharmacokinetic parameters for meloxicam were determined following single intravenous (i.v.), intramuscular (i.m.) and oral (p.o.) administrations of the drug (1 mg/kg·b.w.) in adult African grey parrots (Psittacus erithacus; n = 6). Serial plasma samples were collected and meloxicam concentrations were determined using a validated high-performance liquid chromatography assay. A noncompartmental pharmacokinetic analysis was performed. No undesirable side effects were observed during the study. After i.v. administration, the volume of distribution, clearance and elimination half-life were 90.6 ± 4.1 mL/kg, 2.18 ± 0.25 mL/h/kg and 31.4 ± 4.6 h, respectively. The peak mean ± SD plasma concentration was 8.32 ± 0.95 µg/mL at 30 min after i.m. administration. Oral administration resulted in a slower absorption (tmax  = 13.2 ± 3.5 h; Cmax  = 4.69 ± 0.75 µg/mL) and a lower bioavailability (38.1 ± 3.6%) than for i.m. (78.4 ± 5.5%) route. At 24 h, concentrations were 5.90 ± 0.28 µg/mL for i.v., 4.59 ± 0.36 µg/mL for i.m. and 3.21 ± 0.34 µg/mL for p.o. administrations and were higher than those published for Hispaniolan Amazon parrots at 12 h with predicted analgesic effects.

Prevalence and types of hyponatraemia, its relationship with hyperglycaemia and mortality in ill pet rabbits.

Prevalence of hyponatraemia has not been extensively studied in pet rabbits, and the reference data for calculated plasma tonicity and osmolarity are not available. This retrospective clinical study reports the prevalence of hyponatraemia, hyposmolarity and hypotonicity in ill pet rabbits (n=356). The relationship between sodium and glucose levels was studied (n=134). Mortality rates within seven days associated with different sodium levels were calculated in ill rabbits (n=322). Venous blood samples in lithium heparin were processed using iStat EC8+ cartridges. The 95% RI for plasma sodium, calculated osmolarity and tonicity from 51 healthy pet rabbits were 136-147 mEq/l, 284-312 mOsm/l and 278-302 mOsm/l, respectively. The prevalence of hyponatraemia, hypotonicity and hyposmolarity was 39.0 per cent, 28.7 per cent and 18.0 per cent, respectively. Pseudohyponatraemia was present in 28.1 per cent and true hyponatraemia was present in 71.9 per cent of the cases of hyponatraemia. Sodium levels less than 129 mEq/l were found to be associated with 2.3-fold increase in mortality risk. Plasmatic sodium levels in rabbits decrease in conditions of hyperglycaemia in a similar manner as it occurs in human beings. As hyperglycaemia is quite a common condition in rabbits, simultaneous measurement of plasmatic sodium along with glucose in ill rabbits is advised. Hyponatraemia is a common condition in ill rabbits and, depending on its type (true hyponatraemia or pseudohyponatraemia), of varying clinical relevance. Calculation of plasmatic tonicity is necessary for differentiation of types of hyponatraemia.

Congestive heart failure in 6 African grey parrots (Psittacus e erithacus).

Six African grey parrots (Psittacus e erithacus) were diagnosed with cardiomyopathy and congestive heart failure based on gross and microscopic findings. Ages ranged from 15 days to 8 years, and 5 of 6 parrots were either neonates or juveniles at the time of diagnosis. Two neonates and 2 juveniles came from the same breeding aviary; the 2 juveniles were born to the same breeding pair. The 2 other parrots were kept as pets. Clinical signs included distention of the coelomic cavity (4 of 6), rales (3 of 6), weakness (4 of 6), bradyarrhythmia (1 of 6), growth retardation (1 of 6), crop stasis (1 of 6), and regurgitation (1 of 6). Three parrots were euthanized and 3 died. Gross findings included cardiomegaly due to biventricular, right-, or left-sided cardiomyopathy (6 of 6); coelomic effusion (6 of 6); whitish or yellow foci in the liver (6 of 6); atrophy of the liver (particularly, the left lobe; 5 of 6); reddened or grey lungs (5 of 6); subcutaneous edema (2 of 6); hydropericardium (1 of 6); and bilateral thyroid gland enlargement (1 of 6). Relevant microscopic findings included passive hepatic congestion (6 of 6) and pulmonary congestion (2 of 6), lymphocytic thyroiditis (2 of 6), and diffuse thyroid follicular hyperplasia (2 of 6). Microscopically, the heart was unremarkable (2 of 6) or had mild lymphocytic myocarditis (2 of 6), mild multifocal cytoplasmic vacuolation of cardiomyocytes (2 of 6), mild lymphocytic myocardial (Purkinje cell) ganglioneuritis (1 of 6), and mild multifocal interstitial fibrosis and nuclear hypertrophy of cardiomyocytes (1 of 6). One parrot had concurrent proventricular dilatation disease (systemic ganglioneuritis). The cause of cardiomyopathy in these parrots was not determined.

Clinicopathologic features of a systemic coronavirus-associated disease resembling feline infectious peritonitis in the domestic ferret (Mustela putorius).

From 2002 to 2007, 23 ferrets from Europe and the United States were diagnosed with systemic pyogranulomatous inflammation resembling feline infectious peritonitis (FIP). The average age at the time of diagnosis was 11 months. The disease was progressive in all cases, and average duration of clinical illness was 67 days. Common clinical findings were anorexia, weight loss, diarrhea, and large, palpable intra-abdominal masses; less frequent findings included hind limb paresis, central nervous system signs, vomiting, and dyspnea. Frequent hematologic findings were mild anemia, thrombocytopenia, and hypergammaglobulinemia. Grossly, whitish nodules were found in numerous tissues, most frequently the mesenteric adipose tissue and lymph nodes, visceral peritoneum, liver, kidneys, spleen, and lungs. One ferret had a serous abdominal effusion. Microscopically, pyogranulomatous inflammation involved especially the visceral peritoneum, mesenteric adipose tissue, liver, lungs, kidneys, lymph nodes, spleen, pancreas, adrenal glands, and/or blood vessels. Immunohistochemically, all cases were positive for coronavirus antigen using monoclonal antibody FIPV3-70. Electron microscopic examination of inflammatory lesions identified particles with coronavirus morphology in the cytoplasm of macrophages. Partial sequencing of the coronavirus spike gene obtained from frozen tissue indicates that the virus is related to ferret enteric coronavirus.

De la anatomía patológica convencional a los nuevos perfiles genéticos del cáncer de mama / No disponible

La mortalidad por cáncer de mama se ha reducido graciasal diagnóstico precoz y a los tratamientos adyuvantes. Losefectos secundarios, toxicidades potenciales y el coste de lostratamientos sistémicos condicionan la individualización terapéuticacon una mejor selección de las pacientes. La heterogeneidaddel cáncer de mama nos obliga a considerar los factorespronósticos y predictivos.Desde hace 25 años clasificamos el cáncer de mama según sutipo histológico, grado y expresión de los receptores hormonales.Desde hace 15 años, gracias a la aplicación de las técnicas dehibridación in situ de los ácidos nucleicos, los tumores se clasificanen HER2 sobre-expresado o no sobre-expresado. Desdehace menos de 5 años se han definido distintos patrones de expresióngenética que nos aportan una nueva clasificación molecular.Perou y Sorlie publicaron el estudio pionero en Nature2000, demostrando que la heterogeneidad morfológica de los tumoresmamarios puede reclasificarse en 4 grupos principales: luminalA, luminal B, HER2 amplificado y similar a basal (basallike)en base a los estudios de reordenamiento genético. Los dosprimeros son de mejor pronóstico y el basal-like está relacionadocon un comportamiento más agresivo, con tendencia a desarrollarmetástasis y con un fenotipo “triple negativo” (para los receptoresde estrógenos, de progesterona y para el HER2), quelos excluye de las terapias diana hormonal y anti HER2, y aunquepueden responder bien a la quimioterapia neoadyuvante yadyuvante, su pronóstico es malo.De la misma manera la cuantificación de ciertos genes y suponderación según el impacto en su valor predictivo, ha sidocrucial para obtener los llamados tests genéticos predictivos...(AU)

Breast cancer mortality has declined as a result of early detectionand application of adjuvant systemic therapy. Individualisationof this therapy regarding the selection of patientsmay avoid side effects, potential toxicities and cost of adjuvanttherapy. The heterogenecity of breast cancer oblige us to considerprognostic and predictive factors.Invasive breast carcinomas were classified, since 25 yearsago, according to histological type, grade and expression ofhormone receptors. Fifteen years ago and thanks to the introductionof the hybridization in situ of nucleic acids techniques,we could classify breast tumors in HER2 amplified and not amplifiedHER2. More recently, the molecular portraits or variationin gene expression patterns by Perou and Sorlie (Nature2000), have demonstrated that the morphological heterogenecityof breast cancer could be reclassified based in theDNA microarrays analysis studies. These studies have shownthat the expression profiles of breast cancer display a systematicvariation and allowed the classification of breast cancer into4 main groups: luminal A, luminal B, amplified Her2 and basallikebreast carcinomas. The first two groups have better prognosisand the latter group is reported to have a more aggressiveclinical behaviour. In addition, the majority of basal-like breastcancers are hormone receptors and HER2 negative (triple-negative),and thus cannot be targeted with current tailored therapies(i.e. endocrine and anti-HER2 therapies), but they oftenrespond to conventional neoadjuvant and adjuvant chemotherapyregimes, furthermore their prognosis remains poor.In the same way the quantification of certain genes andtheir weighting according to their impact on predictive value,has been crucial to obtain the so-called predictive genetic test.The diagnostic and therapeutic challenge posed by this newapproach has captured the attention of specialist implied inbreast cancer research(AU)

Trimethoprim-sulfamethoxazole-induced cholestasis.

A 52-year old woman developed severe cholestasis seven days after the administration of trimethoprim-sulfamethoxazole (RMP-SMZ) The clinical and pathologic features are discussed as well as the various mechanisms of liver injury following TMP-SMZ use.